Molecular pathogenesis of autosomal recessive polycystic kidney disease (ARPKD): Fibrocystin as a regulator of cell metabolism and mitochondrial function
Molecular pathogenesis of autosomal recessive polycystic kidney disease (ARPKD): Fibrocystin as a regulator of cell metabolism and mitochondrial function
批准号:
430863862
负责人:
Professor Dr. Max Christoph Liebau
金额:
$0.0万
依托单位国家:
德国
项目类别:
Research Grants
财政年份:
--
资助国家:
德国
项目状态:
未结题
起止时间:
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Autosomal recessive polycysitc kidney disease (ARPKD) is a severe genetic disorder of early childhood that is typically characterized by intrauterine enlargement of fibrocystic kidneys resulting in early-onset end stage renal disease and obligatory hepatic involvement presenting as congenital hepatic fibrosis. The molecular pathogenesis of ARPKD and the cellular function of the affected protein fibrocystin (FC) remain incompletely understood. It has been suggested that FC may influence the same intracellular signaling cascades as the two proteins mainly affected in the more common autosomal dominant polycystic kidney disease (ADPKD). Overlapping clinical and genetic findings between ARPKD and ADPKD have been described.To gain insight into the molecular function of FC, we characterized various cellular models, including patient-derived cell lines and transgenic cell lines, and e.g. obtained cellular signatures by RNASeq and proteome analyses as well as mass spectromtry-based studies of the FC interactome. Findings from these experiments suggest that FC may, in addition to its function at the cellular cilium, contribute to the regulation of cellular metabolism. Celllular metabolic reprogramming has been described for ADPKD by various independent groups.In the suggested project we examine a potential link between FC and changes of the renal-tubular cell metabolism and mitochondria in ARPKD in detail and thus analyze whether cell metabolic processes could serve as a potential therapeutic target in ARPKD. By using CRISPR/Cas9-based PKHD1-deficient human cellular models we will characterize FC-dependent effects on general cellular aspects. We will then define specific metabolic signaling profiles and study mitochondrial function, morphology and protein composition. In an in vivo approach the role of Caveolin-1, a candidate for a FC-interacting protein identified in our previous work, for the renal and hepatic phenotype will be described by using a murine ARPKD modell and generating a double knockout mouse.In summary, the results of this project will give insights into the pathogenesis of ARPKD and may serve as a starting point for first targeted therapeutic strategies for one of the most devastating pediatric renal diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
配子生成素GGN不同位点突变损伤分子伴侣BIP及HSP90B1功能导致精子形成障碍的发病机理
-
批准号:82371616
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:姚晨成
-
依托单位:
Pik3r2基因突变在家族内侧颞叶癫痫中的作用及发病机制研究
-
批准号:82371454
-
项目类别:面上项目
-
资助金额:47.00万元
-
批准年份:2023
-
负责人:郝勇
-
依托单位:
cGAS-STING通路调控单核细胞活化参与Graves病发病的机制研究
-
批准号:82370787
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:王曙
-
依托单位:
间皮细胞衰老在腹膜透析后腹膜适应不良修复和纤维化发病中的作用及机制研究
-
批准号:82370743
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:姜娜
-
依托单位:
成骨谱系功能异常在X-连锁显性低血磷性佝偻病/骨软化症发病中的作用与机制研究
-
批准号:82370888
-
项目类别:面上项目
-
资助金额:65.00万元
-
批准年份:2023
-
负责人:李珊珊
-
依托单位:
miR-126 介导的人参皂苷 Rg1 治疗阿尔茨海默病机制研究
-
批准号:2021JJ30512
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:杨岩涛
-
依托单位:
肥大细胞-T细胞相互作用影响间质性膀胱炎病理发生的分子机制研究
-
批准号:81170700
-
项目类别:面上项目
-
资助金额:65.0万元
-
批准年份:2011
-
负责人:刘武江
-
依托单位:
年龄和手术应激强度在术后远期认知功能障碍发生中的作用与机制研究
-
批准号:81141066
-
项目类别:专项基金项目
-
资助金额:10.0万元
-
批准年份:2011
-
负责人:王东信
-
依托单位:
MBL和ficolin受体的鉴定及其在SLE发病中作用
-
批准号:30972719
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2009
-
负责人:刘昱
-
依托单位:
内质网应激在退行性骨关节病发生发展中的作用研究
-
批准号:30772198
-
项目类别:面上项目
-
资助金额:27.0万元
-
批准年份:2007
-
负责人:曹永平
-
依托单位: